Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer’s disease-associated pathology in transgenic mice

American Journal of Pathology

Volumn 159, Issue 2, 2001, Pages 439-447

  Sigurdsson, Einar M ^a   Scholtzova, Henrieta ^a   Mehta, Pankaj D ^b   Frangione, Blas ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BRAIN PROTEIN; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG SAFETY; HIPPOCAMPUS; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNIZATION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION;

EID: 0034884382     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61715-4     Document Type: Article

References (50)

1. Biochemical detection of Aβ isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease
2. The pathogenesis of Alzheimer's disease. Is amyloid β-protein the beginning or the end?
3. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein
4. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease
5. Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats
6. Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: Behavioral, neurochemical, and time dependent histopathological effects
7. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain
8. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
9. In vivo reversal of amyloid-β lesions in rat brain
10. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
11. Disaggregation of Alzheimer β-amyloid by site-directed mAb
12. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide
13. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
14. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
15. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
16. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
17. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
18. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology
19. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
20. Fact and speculation on the function of immune response genes in antigen presentation
21. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity
22. The antigenic index: A novel algorithm for predicting antigenic determinants
23. Alzheimer's β-amyloid peptide is conformationally modified by apolipoprotein E in vitro
24. Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: A practical guide
25. Cerebrospinal fluid inhibits Alzheimer β-amyloid fibril formation in vitro
26. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
27. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
28. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
29. Antibodies directed to the carboxyl terminus of amyloid β-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain
30. Increased plasma amyloid β protein 1-42 levels in Down syndrome
31. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
32. Detection and quantification of amyloid β-peptide with 2 monoclonal antibodies
33. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain
34. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3
35. Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding
36. Stereological methods for estimating the total number of neurons and synapses: Issues of precision and bias
37. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity
38. Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure
39. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis
40. Blood-brain barrier transport of circulating Alzheimer's amyloid β
41. Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier
42. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs
43. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier
44. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy
45. Receptor-mediated transport of human amyloid β-protein 1-40 and 1-42 at the blood-brain barrier
46. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
47. Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
48. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease
49. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
50. Inflammation and Alzheimer's disease